人ProIGF-IE(71 - 86)抗血清通過用衍生自與白喉類毒素連接的人ProIGF-IE的E結(jié)構(gòu)域的16個(gè)氨基酸的肽免疫兔來制備。 肽序列位于成熟IGF-I的C末端切割位點(diǎn)的緊下游,因此,抗血清識(shí)別所有來源于人igf-1基因可變剪接的ProIGF-I E蛋白。 它不識(shí)別成熟的IGF-I或IGF-II。 由于igf-1基因的選擇性剪接,它可能在非人靈長(zhǎng)類動(dòng)物、兔和豚鼠中識(shí)別ProIGF-I E蛋白,但在其它物種中不識(shí)別。 Human ProIGF-I E (71-86) antiserum was prepared by immunising rabbits with a 16 amino acid peptide derived from the E domain of human ProIGF-I E linked to diphtheria toxoid. The peptide sequence is located immediately downstream of the cleavage site at the C terminus of mature IGF-I and as a consequence, the antiserum recognises all ProIGF-I E proteins derived from alternative splicing of the human igf-1 gene. It does not recognise mature IGF-I or IGF-II. It is likely to recognise ProIGF-I E proteins in non-human primates, rabbits and guinea-pigs but not other species due to alternative splicing of the igf-1 gene.
GroPep Bioreagents公司總部位于澳大利亞,成立于1990年,致力于向廣大科研院所、生物技術(shù)及制藥公司開發(fā)、生產(chǎn)和銷售細(xì)胞培養(yǎng)級(jí)的活性生長(zhǎng)因子(主要集中在胰島素樣生長(zhǎng)因子(IGF)領(lǐng)域)、抗體及相關(guān)蛋白試劑,現(xiàn)有產(chǎn)品超過100多個(gè),同時(shí)在世界范圍內(nèi)均設(shè)有分銷商。公司在分子生物領(lǐng)域、發(fā)酵學(xué)及重組蛋白和單抗制備方面具有豐富的經(jīng)驗(yàn),在制造工藝方面,擁有大量專利技術(shù),GroPep目前已通過AS/NZS ISO 9001:2016質(zhì)量管理體系認(rèn)證。